Vernalis and Servier have achieved two milestones in their oncology discovery collaborations, triggering a payment of €750K to Vernalis. The companies initiated their first collaboration in May 2007 utilizing Vernalis’ fragment and structure-based drug discovery platform on several oncology targets, one of which is Bcl-2. Vernalis receives fees, development milestones, and royalties on potential sales. Financial terms were not disclosed. Ian Garland, chief executive officer of Vernalis...